Prevention and genetic testing variations in medical for breast cancer: decisions

被引:39
作者
Bouchard, L
Blancquaert, I
Eisinger, F
Foulkes, WD
Evans, G
Sobol, H
Julian-Reynier, C
机构
[1] Univ Ottawa, Sociol & Populat Hlth Inst, Ottawa, ON K1N 6N5, Canada
[2] Agcy Hlth Serv & Technol Assessment, Montreal, PQ H3A 2S9, Canada
[3] Inst J Paoli I Calmettes, INSERM, U379, F-13009 Marseille, France
[4] INSERM, EPl9939, F-13009 Marseille, France
[5] McGill Univ, Program Ganc Genet, Dept Oncol, Montreal, PQ H2W 1S6, Canada
[6] McGill Univ, Dept Human Genet, Montreal, PQ H2W 1S6, Canada
[7] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England
关键词
breast cancer; genetic testing; medical decision-making;
D O I
10.1016/S0277-9536(03)00263-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The discovery linking the genes BRCA1&2 to familial breast cancer played an important role in the clinical practice of geneticists and physicians. The availability of genetic tests for BRCA gene mutations prompted cancer geneticists to give information about genetic risk and to assess many women with a personal or family history of breast or ovarian cancer to inform them of preventive measures. These consist mainly of breast self-examination, mammography screening, chemoprevention and prophylactic surgery (mastectomy, oophorectomy). This paper examines clinical practices related to hereditary breast cancer testing and introduces a number of results from a survey carried out, between 1996 and 1998, in three clinics located in Montreal (Quebec, Canada), Marseilles (France) and Manchester (Great Britain). Results show substantial differences in the way cancer geneticists deal with environmental risk factors, breast and ovarian cancer testing, and chemoprevention and prophylactic surgery. Differences across cities persist in the multivariate analysis, suggesting that attitudes towards preventive measures may be partially explained by cultural factors. Different dimensions of culture are discussed including the social representation of health and risk, the interpretation of scientific evidence and the role of innovation leadership. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1085 / 1096
页数:12
相关论文
共 50 条
[1]  
[Anonymous], BREAKTHROUGH RACE FI
[2]   Assessing the risk of breast cancer. [J].
Armstrong, K ;
Eisen, A ;
Weber, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :564-571
[3]   Trajectories of collaboration and competition in a medical discovery [J].
Atkinson, P ;
Batchelor, C ;
Parsons, E .
SCIENCE TECHNOLOGY & HUMAN VALUES, 1998, 23 (03) :259-284
[4]  
Batt Sharon., 1994, PATIENT NO MORE POLI
[5]   BRCA1 and BRCA2:: From molecular genetics to clinical medicine [J].
Blackwood, MA ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1969-1977
[6]  
BRUNGER F, 1998, SOCIO ETHICAL ISSUES, P7
[7]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003
[8]   Clinical management of women with genomic BRCA1 and BRCA2 mutations [J].
Chang, J ;
Elledge, RM .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (02) :101-113
[9]  
Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO
[10]  
2-Z